News Release

Gene signature in ovarian cancer predicts survival and offers new drug target

Peer-Reviewed Publication

University of Bradford

Richard Morgan, University of Bradford

image: Richard Morgan is the Director of the University of Bradford's Institute of Cancer Therapeutics. view more 

Credit: University of Bradford

A new UK study has identified a gene signature that predicts poor survival from ovarian cancer. The study also identified genes which help the cancer develop resistance to chemotherapy - offering a new route to help tackle the disease.

The study, published in the International Journal of Cancer, examined the role of HOX genes in ovarian cancer resistance and whether a drug known as HXR9 which targets HOX, could help prevent the resistance from developing.

The HOX gene family enables the remarkably rapid cell division seen in growing embryos. Most of these genes are switched off in adults, but previous research has shown that in several cancers, including ovarian cancer, HOX genes are switched back on, helping the cancer cells to proliferate and survive.

Led by Professor Richard Morgan, Director of the University of Bradford's Institute of Cancer Therapeutics, researchers analysed tissue samples from 99 women with epithelial ovarian cancer (EOC) - the most common form - and compared these with healthy ovarian and fallopian tube tissue samples.

Little to no HOX expression was found in normal ovarian tissue whereas 36 of the 39 HOX genes were found at high levels in tissue samples of the EOC subtype known as 'high grade serous', which accounts for approximately 80% of epithelial ovarian cancers. A strong five-gene signature was found in all patients who succumbed to the disease, irrespective of their length of survival.

The team also conducted extensive tests on cells and preliminary tests on mice using HXR9 - a peptide drug developed by Professor Morgan which blocks the function of the proteins expressed by HOX genes, forcing cancer cells to close down and die.

The team tested both HXR9 and cisplatin, the most common drug currently used to treat ovarian cancer, and a combination of the two. They found that combining the two drugs significantly increased the number of cancer cells which were killed compared to either drug used alone.

Co-author Dr Zoe Kelly, who carried out this research at the University of Surrey, said: "We've identified a set of genes which play a contributing role in resistance to chemotherapy, which is a major problem in the treatment of ovarian cancer. We also have strong and extensive cell line data which shows that using HXR9 can overcome this drug resistance, making the cell more susceptible to chemotherapy treatment.

She added: "The results in mice were encouraging, but more muted: treated mice survived for longer, but the cell killing of the combination approach was only marginally better than HXR9 used on its own. However, these tests were carried out over a very short timeframe, and I believe that more extensive tests in the mouse model would show clearer results. This needs to be the next step for this research."

Professor Morgan said: "This is the first comprehensive analysis of HOX gene expression in ovarian cancer and the first study to analyse changes in HOX expression in resistant cancer cells. The results strongly suggest that targeting these genes as a new treatment approach warrants further investigation. It also supports our belief that HXR9 should be further developed and tested in clinical trials."


This research was supported by GRACE, a gynaecological charity based in Surrey.

The paper, "The prognostic significance of specific HOX gene expression patterns in ovarian cancer" is published in International Journal of Cancer (doi: 10.1002/ijc.30204)

To interview Professor Morgan or for photos, please contact: Jenny Watkinson, Media Relations Officer, University of Bradford: Tel +44 (0)1274 236030 E-mail


About ovarian cancer

Ovarian cancer is the most lethal of the gynaecological cancers. Initially most women respond to platinum-based therapy, but the majority see the cancer return due to drug resistance. Ovarian cancer is the 5th leading cause of cancer death in women in the western world.

In the UK, some 7,000 women are diagnosed with ovarian cancer each year. The UK five-year survival rate for ovarian cancer is 46 per cent. Overall survival rates are among the lowest in Europe.

About the University of Bradford

Founded in 1966, the University of Bradford is one of the UK's 'traditional' universities. It is a research-intensive institution, ranked in the top 50 in the UK for the quality of its research, with three quarters being classed as either world-leading or internationally excellent in the 2014 Research Excellence Framework (REF). The University was ranked No 1 in Yorkshire for employed graduates obtaining professional & managerial level jobs.

Known for its strong emphasis on employability skills and knowledge transfer work with businesses, the University has a truly global make up with over 20 per cent of its student population being international. The University is also a leader in sustainable development and education, and is 8th greenest in the world according to UI GreenMetric World University Rankings 2015.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.